-DOCSTART- -X- O
The -X- _ O
newly-emerging -X- _ O
Middle -X- _ O
East -X- _ O
respiratory -X- _ O
syndrome -X- _ O
coronavirus -X- _ O
( -X- _ O
MERS-CoV -X- _ O
) -X- _ O
can -X- _ O
cause -X- _ O
severe -X- _ O
and -X- _ O
fatal -X- _ O
acute -X- _ O
respiratory -X- _ O
disease -X- _ O
in -X- _ O
humans. -X- _ O
Despite -X- _ O
global -X- _ O
efforts -X- _ O
, -X- _ O
the -X- _ O
potential -X- _ O
for -X- _ O
an -X- _ O
associated -X- _ O
pandemic -X- _ O
in -X- _ O
the -X- _ O
future -X- _ O
can -X- _ O
not -X- _ O
be -X- _ O
excluded. -X- _ O
The -X- _ O
development -X- _ O
of -X- _ O
effective -X- _ O
counter- -X- _ O
measures -X- _ O
is -X- _ O
urgent. -X- _ O
MERS-CoV-specific -X- _ O
anti-viral -X- _ O
drugs -X- _ O
or -X- _ O
vaccines -X- _ O
are -X- _ O
not -X- _ O
yet -X- _ O
available. -X- _ O
Using -X- _ O
the -X- _ O
spike -X- _ B-Patient
receptor-binding -X- _ I-Patient
domain -X- _ I-Patient
of -X- _ I-Patient
MERS-CoV -X- _ I-Patient
( -X- _ I-Patient
MERS-RBD -X- _ I-Patient
) -X- _ I-Patient
to -X- _ I-Patient
immunize -X- _ I-Patient
mice -X- _ I-Patient
, -X- _ O
we -X- _ O
identified -X- _ O
two -X- _ B-Intervention
neutralizing -X- _ I-Intervention
monoclonal -X- _ I-Intervention
antibodies -X- _ I-Intervention
( -X- _ I-Intervention
mAbs -X- _ I-Intervention
) -X- _ I-Intervention
4C2 -X- _ I-Intervention
and -X- _ I-Intervention
2E6. -X- _ I-Intervention
Both -X- _ B-Outcome
mAbs -X- _ I-Outcome
potently -X- _ I-Outcome
bind -X- _ I-Outcome
to -X- _ I-Outcome
MERS- -X- _ I-Outcome
RBD -X- _ I-Outcome
and -X- _ I-Outcome
block -X- _ I-Outcome
virus -X- _ I-Outcome
entry -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
with -X- _ I-Outcome
high -X- _ I-Outcome
efficacy. -X- _ I-Outcome
We -X- _ O
further -X- _ O
investigated -X- _ O
their -X- _ O
mechanisms -X- _ O
of -X- _ O
neutralization -X- _ O
by -X- _ O
crystallizing -X- _ O
the -X- _ O
complex -X- _ O
between -X- _ O
the -X- _ O
Fab -X- _ O
fragments -X- _ O
and -X- _ O
the -X- _ O
RBD -X- _ O
, -X- _ O
and -X- _ O
solved -X- _ O
the -X- _ O
structure -X- _ O
of -X- _ O
the -X- _ O
4C2 -X- _ O
Fab -X- _ O
/ -X- _ O
MERS-RBD -X- _ O
complex. -X- _ O
The -X- _ B-Outcome
structure -X- _ I-Outcome
showed -X- _ I-Outcome
that -X- _ I-Outcome
4C2 -X- _ I-Outcome
recognizes -X- _ I-Outcome
an -X- _ I-Outcome
epitope -X- _ I-Outcome
that -X- _ I-Outcome
partially -X- _ I-Outcome
overlaps -X- _ I-Outcome
the -X- _ I-Outcome
receptor-binding -X- _ I-Outcome
footprint -X- _ I-Outcome
in -X- _ I-Outcome
MERS-RBD -X- _ I-Outcome
, -X- _ I-Outcome
thereby -X- _ I-Outcome
interfering -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
virus -X- _ I-Outcome
/ -X- _ I-Outcome
receptor -X- _ I-Outcome
interactions -X- _ I-Outcome
by -X- _ I-Outcome
both -X- _ I-Outcome
steric -X- _ I-Outcome
hindrance -X- _ I-Outcome
and -X- _ I-Outcome
interface-residue -X- _ I-Outcome
competition. -X- _ I-Outcome
2E6 -X- _ I-Outcome
also -X- _ I-Outcome
blocks -X- _ I-Outcome
receptor -X- _ I-Outcome
binding -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
competes -X- _ I-Outcome
with -X- _ I-Outcome
4C2 -X- _ I-Outcome
for -X- _ I-Outcome
binding -X- _ I-Outcome
to -X- _ I-Outcome
MERS-RBD. -X- _ I-Outcome
Based -X- _ I-Outcome
on -X- _ I-Outcome
the -X- _ I-Outcome
structure -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
further -X- _ I-Outcome
humanized -X- _ I-Outcome
4C2 -X- _ I-Outcome
by -X- _ I-Outcome
preserving -X- _ I-Outcome
only -X- _ I-Outcome
the -X- _ I-Outcome
paratope -X- _ I-Outcome
residues -X- _ I-Outcome
and -X- _ I-Outcome
substituting -X- _ I-Outcome
the -X- _ I-Outcome
remaining -X- _ I-Outcome
amino -X- _ I-Outcome
acids -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
counterparts -X- _ I-Outcome
from -X- _ I-Outcome
human -X- _ I-Outcome
immunoglobulins. -X- _ I-Outcome
The -X- _ I-Outcome
humanized -X- _ I-Outcome
4C2 -X- _ I-Outcome
( -X- _ I-Outcome
4C2h -X- _ I-Outcome
) -X- _ I-Outcome
antibody -X- _ I-Outcome
sustained -X- _ I-Outcome
similar -X- _ I-Outcome
neutralizing -X- _ I-Outcome
activity -X- _ I-Outcome
and -X- _ I-Outcome
biochemical -X- _ I-Outcome
characteristics -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
parental -X- _ I-Outcome
mouse -X- _ I-Outcome
antibody. -X- _ I-Outcome
Finally -X- _ O
, -X- _ O
we -X- _ O
showed -X- _ O
that -X- _ O
4C2h -X- _ B-Outcome
can -X- _ I-Outcome
significantly -X- _ I-Outcome
abate -X- _ I-Outcome
the -X- _ I-Outcome
virus -X- _ I-Outcome
titers -X- _ I-Outcome
in -X- _ I-Outcome
lungs -X- _ I-Outcome
of -X- _ I-Outcome
Ad5-hCD26-transduced -X- _ I-Outcome
mice -X- _ I-Outcome
infected -X- _ I-Outcome
with -X- _ I-Outcome
MERS-CoV -X- _ I-Outcome
, -X- _ O
therefore -X- _ O
representing -X- _ O
a -X- _ O
promising -X- _ O
agent -X- _ O
for -X- _ O
prophylaxis -X- _ O
and -X- _ O
therapy -X- _ O
in -X- _ O
clinical -X- _ O
settings -X- _ O
. -X- _ O

